& Marian, E
On February 6, however, FDAs approach appeared to shift with an announcement that it would be taking steps both to restrict GLP-1 active pharmaceutical ingredients (APIs) that continue to be used in non-FDA-approved compounded products to combat misleading direct-to-consumer advertising and marketing. Unequivocally, FDA warned: Entities engaged in the manufacture, distribution, or marketing of unapproved compounded GLP-1 products should be aware that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. FDA specifically named Hims & Hers a popular and outspoken telehealth provider that advertises compounded GLP-1 products in the announcement
ARROW, Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
At 12 weeks no muscle carnitine differences were apparent between the groups
Ensure you use your medications within the recommended period for optimal results and safety
